Obesity & weight management
3 trials- 2022SURMOUNT-1Tirzepatide for obesityIn 2,539 adults with obesity without type 2 diabetes, tirzepatide 5, 10 or 15 mg weekly reduced body weight at 72 weeks compared with placebo.
- 2021STEP 1Semaglutide for obesityIn 1,961 adults with overweight or obesity without type 2 diabetes, subcutaneous semaglutide 2.4 mg weekly reduced body weight at 68 weeks compared with placebo.
- 2013Look AHEADLifestyle interventionIn 5,145 patients with T2DM and BMI ≥25, intensive lifestyle intervention did not reduce cardiovascular events compared with diabetes support and education.